Drug Trial Radar · NCT06798012
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 14, 2025
Primary completion
Dec 2, 2027
Study completion Jun 8, 2028
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP. The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial. Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose. During the study, participants may visit their study clinic up to approximately 21 times.
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-411Biological
TAK-411 IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Improvement in Functional Ability at Week 24Time frame: At Week 24
Locations
22 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California · Recruiting
California Pacific Medical Center
San Francisco, California · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
UF Health Neurology - Jacksonville
Jacksonville, Florida · Recruiting
Visionary Investigators Network
Miami, Florida · Recruiting
Knight Neurology
Rockledge, Florida · Recruiting
University of South Florida
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
The Curators of the University of Missouri on behalf of University of Missouri Health Care
Columbia, Missouri · Recruiting
The Washington University
St Louis, Missouri · Recruiting
Velocity Clinical Research - Raleigh
Raleigh, North Carolina · Recruiting
Penn Blood Disorders Program - Hospital of The University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
University of Washington
Seattle, Washington · Recruiting
University of Calgary
Calgary, Alberta, Canada · Recruiting
University Health Network
Toronto, Ontario, Canada · Recruiting
Universidad del Rosario
Bogotá, Colombia · Recruiting
Fundacion Oftalmologica de Santander - FOSCAL
Bucaramanga, Colombia · Recruiting
Neuro ClinicaS.A.S
Medellín, Antioquia, Colombia · Recruiting
Hospital Universitario San Ignacio
Bogotá, D.C., Colombia · Recruiting
Fundacion Valle del Lili
Cali, Valle del Cauca Department, Colombia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.